Study details
Enrolling now
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
David Wilson
NCT IDNCT05374278ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
102
Study length
about 5.6 years
Ages
40–75
Locations
1 site in CA
About this study
Researchers are testing a new imaging agent, called [18F]RP-115, to see if it can help detect early changes in the brains of people with Alzheimer's disease or frontotemporal dementia. The trial will use PET/MRI or PET/CT scans.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take [18F]RP-115 PET/MRI or PET/CT and MRI
PhasePhase 1/Phase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Neurology